Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

716
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
716
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

1
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
1
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

5.1K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
5.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

10.9K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.9K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

10.2K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.2K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

631
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
631

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Achievement of intermediate treatment targets for Still's disease under tocilizumab treatment: a post-hoc analysis of the phase III trial.

Immunological medicine·2026
Same author

Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).

RMD open·2026
Same author

The guide for the diagnosis and treatment of connective tissue disease-associated interstitial lung disease 2025.

Respiratory investigation·2026
Same author

Long-term safety and efficacy of tocilizumab in adult-onset Still's disease: open-label, long-term extension of the phase III trial.

Rheumatology (Oxford, England)·2026
Same author

Ultrasound evaluation of finger joint cartilage damage progression in patients with rheumatoid arthritis.

Therapeutic advances in musculoskeletal disease·2026
Same author

The prediction of a good therapeutic response and outcome: at baseline or after a short term?

Clinical rheumatology·2026

Related Experiment Video

Updated: Mar 19, 2026

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.6K

[TNF inhibitors].

Hideto Kameda

    Nihon Rinsho. Japanese Journal of Clinical Medicine
    |June 18, 2016
    PubMed
    Summary
    This summary is machine-generated.

    For rheumatoid arthritis (RA), tumor necrosis factor (TNF) inhibitors combined with methotrexate show improved effectiveness. Maintaining drug levels during remission induction is key, with tapering possible after sustained remission.

    More Related Videos

    Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
    16:07

    Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

    Published on: September 16, 2017

    9.7K
    Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
    09:51

    Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

    Published on: July 26, 2017

    13.1K

    Related Experiment Videos

    Last Updated: Mar 19, 2026

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
    08:19

    Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

    Published on: July 20, 2019

    6.6K
    Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method
    16:07

    Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody mAb by Neutralizing TNF Using an In Vitro Bioanalytical Method

    Published on: September 16, 2017

    9.7K
    Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling
    09:51

    Screening Bioactive Nanoparticles in Phagocytic Immune Cells for Inhibitors of Toll-like Receptor Signaling

    Published on: July 26, 2017

    13.1K

    Area of Science:

    • Rheumatology
    • Immunology
    • Pharmacology

    Background:

    • Five originator TNF inhibitors and one infliximab biosimilar were available for RA in Japan as of January 2016.
    • Concomitant methotrexate enhances the efficacy and effectiveness of TNF inhibitors in RA patients.
    • The Japan College of Rheumatology updated its TNF inhibitor guideline in March 2015, incorporating recent evidence.

    Purpose of the Study:

    • To summarize the landscape of TNF inhibitor availability and use in rheumatoid arthritis (RA) in Japan.
    • To highlight the importance of methotrexate in conjunction with TNF inhibitors for RA treatment.
    • To present updated guidelines for TNF inhibitor use in RA based on recent evidence.

    Main Methods:

    • Review of available TNF inhibitors and biosimilars for RA in Japan.
    • Analysis of evidence regarding the combination therapy of TNF inhibitors and methotrexate.
    • Incorporation of postmarketing surveillance data into updated clinical guidelines.

    Main Results:

    • TNF inhibitors, including infliximab, etanercept, adalimumab, golimumab, and certolizumab pegol, are established RA treatments in Japan.
    • Methotrexate significantly improves TNF inhibitor effectiveness in RA.
    • Updated guidelines emphasize maintaining effective drug trough levels for remission induction and consider tapering after sustained remission.

    Conclusions:

    • Combination therapy with methotrexate is crucial for optimizing TNF inhibitor treatment in RA.
    • Strategic management of drug trough levels is essential for successful RA remission induction.
    • Guidelines support the consideration of TNF inhibitor tapering in patients with sustained RA remission.